PMID- 28734639
OWN - NLM
STAT- MEDLINE
DCOM- 20171108
LR  - 20220129
IS  - 1873-3735 (Electronic)
IS  - 0165-6147 (Print)
IS  - 0165-6147 (Linking)
VI  - 38
IP  - 9
DP  - 2017 Sep
TI  - FFA4/GPR120: Pharmacology and Therapeutic Opportunities.
PG  - 809-821
LID - S0165-6147(17)30127-X [pii]
LID - 10.1016/j.tips.2017.06.006 [doi]
AB  - Free Fatty Acid receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled 
      receptor (GPCR) responsive to long-chain fatty acids that is attracting 
      considerable attention as a potential novel therapeutic target for the treatment 
      of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been 
      initiated to assess efficacy in this indication, a significant number of primary 
      publications and patents have highlighted the ability of agonists with potency at 
      FFA4 to improve glucose disposition and enhance insulin sensitivity in animal 
      models. However, the distribution pattern of the receptor suggests that targeting 
      FFA4 may also be useful in other conditions, ranging from cancer to lung 
      function. Here, we discuss and contextualise the basis for these ideas and the 
      results to support these conclusions.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Milligan, Graeme
AU  - Milligan G
AD  - Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems 
      Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
      Glasgow, G12 8QQ, UK. Electronic address: Graeme.Milligan@glasgow.ac.uk.
FAU - Alvarez-Curto, Elisa
AU  - Alvarez-Curto E
AD  - Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems 
      Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
      Glasgow, G12 8QQ, UK.
FAU - Hudson, Brian D
AU  - Hudson BD
AD  - Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems 
      Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
      Glasgow, G12 8QQ, UK.
FAU - Prihandoko, Rudi
AU  - Prihandoko R
AD  - Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems 
      Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
      Glasgow, G12 8QQ, UK.
FAU - Tobin, Andrew B
AU  - Tobin AB
AD  - Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems 
      Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, 
      Glasgow, G12 8QQ, UK. Electronic address: Andrew.Tobin@glasgow.ac.uk.
LA  - eng
GR  - BB/K019864/1/BB_/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
PT  - Journal Article
PT  - Review
DEP - 20170719
PL  - England
TA  - Trends Pharmacol Sci
JT  - Trends in pharmacological sciences
JID - 7906158
RN  - 0 (FFAR4 protein, human)
RN  - 0 (FFAR4 protein, mouse)
RN  - 0 (Receptors, G-Protein-Coupled)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Receptors, G-Protein-Coupled/*agonists/*antagonists & inhibitors
PMC - PMC5582618
OTO - NOTNLM
OT  - G protein-coupled receptor
OT  - cancer
OT  - diabetes
OT  - free fatty acid
OT  - lung function inflammation
EDAT- 2017/07/25 06:00
MHDA- 2017/11/09 06:00
PMCR- 2017/09/01
CRDT- 2017/07/24 06:00
PHST- 2017/05/08 00:00 [received]
PHST- 2017/06/14 00:00 [revised]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2017/11/09 06:00 [medline]
PHST- 2017/07/24 06:00 [entrez]
PHST- 2017/09/01 00:00 [pmc-release]
AID - S0165-6147(17)30127-X [pii]
AID - 10.1016/j.tips.2017.06.006 [doi]
PST - ppublish
SO  - Trends Pharmacol Sci. 2017 Sep;38(9):809-821. doi: 10.1016/j.tips.2017.06.006. 
      Epub 2017 Jul 19.